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A genetic contribution to MS pathogenesis has been proven ever
since the association with the HLA-DR2 locus was discovered more
than 30 years ago. The search for additional MS risk genes has been
frustrated by a signiﬁcant lack of reproducibility. This was until
recently. In the last two years there have been tremendous break-
throughs in the search for novel risk genes. The main reasons for this
progress have been the introduction of novel techniques, improved
statistical methods and an awareness that nothing can be solved
without extensive international collaboration, including data from
high numbers of patients. As anticipated the effects of these novel
genes are small. In relation with the old stable giant of the associated
HLA locus, the novel dwarfs have woken up, with odds ratios that
generally are below 1.4.
2. Current knowledge
2.1. The genetic component in MS
Although familial aggregation of MS has long been recognized,
systematic age-adjusted recurrence risks for relatives of persons
with MS were ﬁrst published in 1988 [1]. Subsequent studies
showed that ﬁrst-, second- and third-degree relatives of patientswith MS were more likely to have the disease than the general
population. Studies in twins showed a signiﬁcant excess of
concordance in monozygotic as compared to dizygotic twins [2–6].
In a study of individuals with MS who were adopted an excess of
risk in the genetically related family was found, whereas no excess
of risk in the adopting family was found [7]. Affected husband and
wife couples do not occur more frequently than would be expected
by chance. However the risk for their offspring is greater than if just
one parent is affected [8]. For half-siblings the risk is approximately
half the risk for full siblings, regardless whether they were raised
together or apart [9,10]. Together these data suggest that living
with someone who has MS only increases your risk on MS if you are
a relative of that person, in which case your risk increases with
relatedness.2.2. Mode of inheritance in MS
Although, as discussed above, data conﬁrm that genetic factors are
unequivocally relevant in MS, most MS families contain no more than
two or three affected individuals and no clear mode of inheritance can
be inferred from segregation analysis. However the nonlinear
relationship between familial recurrence risk and degree of related-
ness, as well as the available genetic data suggests that between 20
and 100 common variants, each increasing risk by only a modest
factor of 1.2–1.5, would be sufﬁcient to account for the prevalence and
heritability of MS. In addition, it may be possible that rare variants,
with allele frequencies below 5%, play a role, especially in multiplex
MS families [11].
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Several genetic epidemiological studies in MS families have
indicated a skewed maternal transmission of MS [10,12]. However,
another study on patients with affected parents, the quite opposite
ﬁnding of paternal transmission has been presented [13–15]. The likely
explanation for such discrepancies is that more than one mechanism is
at stake. Opposing transmission models (maternal versus paternal) in
individual families could be diluted by inclusion of many small families.
2.4. Parent of origin effects by genetics or epigenetics
A parent-of-origin effect in MS could be the result of several
mechanisms. These may operate differently in alternative inheritance
models for MS: genetic as well as environmental, or both. One of the
possible genetic mechanisms is a threshold effect due to an increased
number of penetrant susceptibility genes in a given parental lineage.
Another possibility is the involvement of epigenetic mechanisms in
disease transmission by the affected parent. Epigenesis means that
there are chromatin and DNAmodiﬁcations affecting gene expression.
These modiﬁcations are transmitted through cell division, but do not
inﬂuence the underlying DNA sequence of that person. If epigenesis
occur early in life, it can affect the availability of the critical gene
product or modify the risk associated with a given gene polymor-
phism. Epigenetic effects do not have to occur in all cells from one
person, they can also operate only in the cells of speciﬁc tissues. The
threshold and epigenetic mechanisms could also occur in conjunction,
especially in complex disorders as MS.
2.5. Susceptibility genes for MS
2.5.1. The HLA region
The ﬁrst recognition of an association of MSwith genes in theMHC
region was in 1972 [16,17]. Until very recently, despite many linkage
and association studies, only the HLA class II region of the HLA-DR2
haplotype on chromosome 6p21 has been shown to be signiﬁcantly
associated with MS. Three candidate risk genes of this haplotype,
HLADRB1*1501 (encoding HLA-DR2b),HLADRB5*0101 (encoding HLA-
DR2a) and HLADQB1*0602 (encoding HLA-DQ6), are so tightly linked
that they are almost invariably inherited together [18]. Therefore
classic genetic studies failed to discriminate between them. More
recently, more powerful genetic studies have implicated
HLADRB1*1501 as the main susceptibility allele in MS [19,20]. The
association is strongest in northern Europeans, but is seen in virtually
all populations with a notable exception in some Mediterranean
populations where MS is associated with DR4. By now it is clear that
HLA DRB1*15 is not the sole risk increasing allele [21].
HLADRB1*17 increases risk for MS, but to a lesser extent than HLA-
DRB1*15 [21,22]. HLADRB1*14 has the most dominant role in MS MHC
genetics and completely abrogates any risk associated with
HLADRB1*15, when they are inherited together. The relative risk of
getting MS for an individual who carries the HLA-DRB1*15 allele is
about 3. HLADRB1*14 together with HLADRB1*15 reduces the relative
risk to approximately 1 [21]. Complex gene–gene interactions, called
“epistasis”, also seem to occur in the HLA region. HLA-DRB1*08 more
than doubles the risk associated with a single copy of HLA-DRB1*15,
whereas on its own, HLA-DRB1*08 has only a modest effect [21].
In addition, HLADRB1*01 and HLADRB1*10 protect against MS but
only in the presence of HLA-DRB1*15 that operate from the other
chromosome— that is in trans [21,23,24], although reports fromSweden
suggest that HLADRB1*01 may be protective on its own [25] (Fig. 1).
Regarding the HLA class I region, it has recently became clear that
there are loci that increase the risk for MS [26,27]. Interestingly, the
class I region involved in EBV-related infectious mononucleosis also
increases the risk forMS [28]. This draws attention to common genetic
backgrounds between MS and primary EBV infection.Epigenetic effects in the HLA region have also been observed in MS.
Using the large Canadian database, it has been possible to study affected
aunt/uncle/niece/nephew (“AUNN”) pairs. It was found that in these
pairs, the allele frequencies for HLA-DRB1*1501were different between
the ﬁrst and second generations affected. HLA-DRB1*15 frequency in
affected males remained the same over the two generations, whereas
affected aunts had signiﬁcantly lower HLA-DRB1*15 frequency com-
pared with their affected nieces. They also found that the risk carried by
HLA-DRB1*15 was greater in families with affected second-degree
relatives (AUNN: OR 4) when compared to those consisting of only
affected ﬁrst-degree relatives (ASP: OR 2). So HLA contributed to risk in
both family types, however the degree of contribution is not the same
and is dependent on family structure and ofMS status of the relatives of
the transmitting individual. This demonstrates heterogeneity of risk
among HLA-DRB1*15 haplotypes based on whether collateral parental
relatives are affected. This study implicates gene–environment interac-
tions in susceptibility [29]. The distorted transmissions may well be
applicable to other non HLA-DRB1*15 alleles, shown to be involved in
susceptibility or resistance. The fact that HLA-DRB1*15 frequency
remained the same over two generations in affected males in contrast
to affected females, suggests that epigenetic modiﬁcations play a role in
the gender bias in MS.
Little is known about the inﬂuence of the presumed environmental
risk factors for MS and the MS risk genes. Some evidence has recently
been provided that vitamin D and infectious mononucleosis (IM)
inﬂuences the risk associated with HLA-DRB1*15. Epidemiological
studies provided strong evidence that the geographical distribution of
MS risk is the result of environmental factors operatingat thepopulation
level. Sunlight, speciﬁcally through its role in generating active vitamin
D, is a likely important environmental factor for the disease [30]. It has
been shown that dietary vitamin D intake reduces disease risk [31] and
thatMSpatients are deﬁcient in vitaminD [32]. VitaminDhas its actions
on immune and central nervous system development and function. So,
vitamin D could inﬂuence MS risk in this way.
Most biological effects of vitamin D are regulated by the vitamin D
receptor (VDR). This receptor inﬂuences the rate of transcription of
vitamin D responsive genes by acting as a ligand activated
transcription factor that binds to vitamin D responsive elements
(VDREs) in gene promotors. Ramagopalan and colleagues localized by
sequence analysis a single MHC vitamin D response element (VDRE)
to the promotor region of HLA-DRB1. Sequencing of this promotor in
chromosomes from HLA-DRB1 homozygotes showed absolute con-
servation of this putative VDRE on HLA-DRB1*15 [24]. Cells transiently
transfected with the HLA-DRB1*15 gene promoter showed increased
expression on stimulation with 1,25-dihydroxyvitamin D3
(P=0.002) that was lost either on deletion of the VDRE or with the
homologous ‘VDRE’ sequence found in non-MS-associated HLADRB1
haplotypes. A speciﬁc increase in the cell surface expression of HLA-
DRB1 upon addition of vitamin D was seen only in HLA-DRB1*15
bearing cells [24]. The biological meaning of this vitamin D induced
speciﬁc HLA class II expression is not clear. It is not directly in linewith
the supposed disease suppressing role of vitamin D. Generally spoken,
higher class II expression is pathogenic. However, more complex
processes may be involved, such as class II induced thymic deletion,
and/or the exact timing of vitamin D effects in human life, for example
in utero. In any case the above effect is a nice example of gene
expression under the inﬂuence of environmental factors.
Finally, class II interactions may exist with EBV induced infectious
mononucleosis (IM). Epidemiological and serological studies also
showed that infectionwith Epstein–Barr virus is associatedwith higher
risk of MS [33,34]. In particular, primary EBV infection, manifesting as
infectious mononucleosis (IM) seems to be associated with increased
MS risk. In a Danish study, IM-naïve individuals, DRB1*15 carried a 2.4-
fold (95% conﬁdence interval [CI], 2.0–3.0) increased MS risk, whereas
personswith IMhistory,DRB1*15was associatedwith a 7.0-fold (95%CI,


























































































































Fig. 1. Genotyping relative risks for MS for combinations of alleles at the HLA-DRB1 locus. x/x=individual with no disease-associated alleles with baseline risk of 1, x=any non-
disease associated allele.
Figure provided by S. Ramagopalan and G.E. Ebers.
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the absence of a history with IM [33].
2.5.2. Non-HLA MS risk SNPs that reached genome-wide signiﬁcance
There are different reasons why until very recently no other risk
genes than the HLA risk gene have been detected. First the
attributable risk of other risk alleles is very small. Furthermore the
populations studied worldwide are quite heterogeneous and a major
factor clearly has been the lack of power statistical.
To overcome the problem of statistical power, the International MS
Genetics Consortium (IMSGC) performed a GWA (genome-wide associ-
ation) study using 500,000 SNP arrays in 931 families. Subsequently they
performed a combined analysis of more than 12000 samples.
The results revealed the existence of 16 other non-MHC suscepti-
bility SNPs in 13 gene loci of modest effect. However only the non-MHC
SNP in the IL2RA gene achieved genome-wide signiﬁcant association
with susceptibility to MS (p=2.96×10−8) (Table 1) [35]. For a third
gene, IL7R, convincing functional support was obtained [36,37]. Later
genome-wide signiﬁcance was established in a joint analysis of 11,019
cases and 13,616 controls [38].
It is of note that the three risk sequence-allelic variants are all
common variants (that is, with a risk allele frequency of N10% and
b90%). It is likely that in MS epistasis and epigenetics occur and result
in direct biological pathways involved in MS.
Follow-up studies and further genome-wide analyses have now
provided genome-wide signiﬁcant support for several non-HLAMS risk
genes [39], amongst which are IL7R, IL2R, CLEC16A [40–42], CD58 [42],
CD226 [40], KIF1B [43], KIF21B [44,45], CD6 [46], IRF8 [46], TNFRSF1A
[46], and two loci on chromosome 12 and 20, which have been
suspected to relate to the genes CD40 and CYP27B1[47,48], TYK2 and
STAT3 [49]. Strikingly most of these molecules are associated with
immune function. It should be noted that the neuronalKIF1B gene could
not be replicated as an MS risk gene by a large consortium [50,51].
2.6. Function of some different identiﬁed risk variants
Inmost situations it is a SNP in or around the gene that is found to be
associated and the real genetic variation associated with MS remains
unknown. In addition, for all of these genes much remains to be
elucidated on the exact place in physiology or in evolution of disease.
Nevertheless, it is of most interest that most of these new MS
susceptibility loci appear to have an important place in the immunesystem. Below we brieﬂy discuss what is known about the function of
the different identiﬁed risk variants. It should be acknowledged here
that this research ﬁeld has a highly dynamic character, and it is virtually
impossible to cover all available knowledge of completely validated and
robust risk loci at a certain timepoint. Also, one has to realise that most
loci have been identiﬁed at the SNP level. Direct proof of the gene
involved is lacking inmost cases.Weherepresent a selection ofwhatwe
consider the current most interesting and robust MS risk loci, and focus
on the functional roles of the likely genes involved.
MHC class II molecules are highly polymorphic cell surface
glycoproteins that present antigen to CD4+ T-helper cells and are
integral to successful maintenance of self-tolerance by the immune
system and the adaptive immune response to invading pathogens [52].
Each HLADRB1 allele forms, by the presence of deﬁned amino acid
anchors, a number of speciﬁc pockets comprising a peptide-binding
groove [53]. The binding afﬁnities for disease-related peptides may
thus be different for different HLADRB1 molecules as determined by
their protein sequence.
Subsequently this may inﬂuence composition of T-cell repertoires
and so this can ultimately results in HLA-DRB1 alleles having varying
effects on disease risk. However protein sequence analysis failed to
provide unequivocal support for this hypothesis. This suggests that
other risk factors are present on HLA-DRB1 haplotypes [54], and this
perhapsdetracts away fromantigenpresentation as the solemechanism
of the MHC association in MS [55].
IL7R encodes for the receptor for interleukin-7, which is expressed
on T and B-lymphocytes. The signal transduced by this receptor is
crucial for lymphocyte survival and immune homeostasis. There are
indications that the exonic IL7R SNP associated with MS leads to less
membrane expressed but more soluble receptor protein, therefore
inﬂuencing receptor signalling [37].
IL2RA encodes for the alpha chain of the interleukin-2 receptor
(IL2R). The involvement of the IL2R chain in the pathogenesis of MS
might also be related to the important role that the IL2–IL2R pathway
plays in adaptive immune functions.
For the CLEC16A protein still little is known regarding its function
in humans. However, it is very likely that it does have a function in
immune function. It is a member of the C-type lectin receptor family,
of which members have described to provide signals for a decision
between tolerance and immunity. They can bind bacterial products as
well as endogenous ligands and their signal can counteract the signal
of Toll-like receptors, therewith inﬂuencing T-helper cell function.
Table 1
Some MS risk genes overlapping with risk genes for other autoimmune diseases.
Gene Chr Function Disease Ref
IL7R 5 Homeostasis of the memory T-cell pool, T1D [89]
IL2R 10 Regulation of T-cells T1D, Graves' disease [90,91]
CLEC16A 16 Provides signals for decisions between
tolerance and immunity
Addison's disease, T1D [40,92]
CD226 Adhesion and co-stimulation T-cells T1D, RA, Graves'disease, Crohn's disease
CYP27B1 12 Hydroxylates 25-hydroxyvitamin D into the
bioactive form
T1D [93]
TNFRSF1A 12 Inﬂuences the TNFα pathway Tumor necrosis factor associated periodic
syndrome (TRAPS)
[94]
CD40 20 Regulator of humoral and cellular immunity RA, Graves' disease [95,96]
CD58 1 Inﬂuences T-cell proliferation and differentiation RA [97]
STAT3 17 Involved in multiple pathways and functions, including
the Jak–STAT pathway, neuron axonal guidance, apoptosis,
activation of immune responses and Th17 cell differentiation
CD, UC, hyper-IgE syndrome [98–101]
T1D: type I diabetes, RA: rheumatoid arthritis, CD: Crohn's disease, UC: ulcerative colitis.
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pathogenesis, and discussed a link with infections [56].
CD226 is a transmembrane receptor of the immunoglobulin receptor
family and is expressed on natural killer cells, T-cells, monocytes and
subsets of B cells and platelets and is implicated in T-cell and NK cell
mediated cytotoxicity andplatelet activation. CD226 recognizes onmost
cell types, includingneurons, endothelial cells andﬁbroblasts, expressed
poliovirus receptor and nectin-2 [57]. Interaction of CD226 with
poliovirus receptor on endothelial cells is involved in endothelial
transmigrationof leukocytes [58]. In autoimmuneencephalomyelitis, an
experimental murine model for multiple sclerosis, anti-CD226 treat-
ment results in reduced severity and delayed onset of the disease. This
could be the result of altered T-cell activation, altered monocyte
extravasation or alterednatural killer cell responsiveness towards target
cells [59].
CD58 encodes a ligand for the T-cell speciﬁc CD2 membrane
molecule, an adhesion molecule that transduces important signals for
T-cell proliferation and differentiation [60].
CD6 is a lymphocyte receptor that belongs to the scavenger
receptor cysteine-rich superfamily. Its expression has also been
reported on certain regions of the brain. CD6 contributes to either
positive or negative modulation of the activation and differentiation
signals for lymphocytes [61,62]. The soluble form of CD6 may also
function as a pattern recognition receptor and affects the serum level
of TNFα in this context in mice [63].
IRF8 is a member of the interferon regulatory factor (IRF) family,
which are speciﬁcally expressed in immune cells. The IRF8 locus
contains an important transcription factor involved in responses to
type I interferons (IFNα and β). Upregulation of interferon responses
has been noted in peripheral blood of a subset of untreated MS
patients [64,65]. However the role of interferons in the onset of MS is
still unclear. Results of a recently performed expression study show
that the susceptibility allele near IRF8 is associated with higher mRNA
expression of interferon-response pathway genes in subjects with MS
[46].
TNFRSF1A encodes the p55 receptor for tumor necrosis factor alpha
(TNFα). Genetic and functional studies suggest that dysregulation of
the TNFα pathway has a role in the onset of MS. Diminished TNFα
activity seems to be associated with onset of CNS inﬂammatory
lesions in clinical studies [66].
CD40 is a member of the tumor necrosis factor receptor superfamily
and is expressed as a co-stimulatory molecule on B cells, dendritic cells,
macrophages and microglia. Together with its ligand CD40L (CD154),
which is expressed on activated CD4+ T-helper cells, CD40 is an
important regulator of both humoral and cellular immunity [67].
CYP27B1 encodes the enzyme 25-hydroxyvitamin D-1 alpha
hydroxylase, which hydroxylates 25-hydroxyvitamin D into the
bioactive form (1,25-dihydroxyvitamin D (1,25(OH)2D). This bioactive
form regulates through the vitamin D receptor (VDR) the calciummetabolism. It also has important immune functionsmodulating innate
as well as adaptive immunity and tolerance [68] and B-cell homeostasis
[69]. Furthermore it can direct activated T-cells toward a T-helper type 2
anti-inﬂammatory phenotype and induce dendritic cells with tolero-
genic properties [70]. Epidemiological data suggest a link between
vitamin D deﬁciency and increased incidence of MS and other
autoimmune diseases [31,71,72].
STAT3 encodes for a transcription factor that is involved inmultiple
pathways and functions, including the Jak–STAT pathway, neuron
axonal guidance, apoptosis, activation of immune responses and Th17
cell differentiation [73]. Mouse studies have shown that the targeted
deletion of STAT3 in CD4+ T-cells prevents the development of
experimental autoimmune encephalomyelitis [74]. Moreover, in-
creased phosphorylated STAT3 was reported in T-cells of patients
evolving from a clinically isolated syndrome to deﬁned MS and in
relapsing patients [75].
TYK2 or tyrosine kinase 2 is a type I interferon signalling enzyme
linked to Th1 cell function. Of note is the fact that TYK2 can activate
STAT3 via tyrosine phophorylation [76], therewith linking twoMS risk
genes in a common pathway.
A very low frequency genetic variant of the gene variant has been
found associated with MS in white and but also African American
individuals [77–79]. It is the ﬁrst rare genetic variant robustly found to
enhance the risk for the disease.
KIF1B and KIF21B, encode for a kinesin superfamily member that
responsible for axonal transport of mitochondria and synaptic vesicle
precursors. KIF1B has an ATP-ase binding domain and is enriched in
motor neurons. Recently dysregulation of ATP-ases and mitochondrial
mislocalization has been shown to play a role in several neurodegen-
erative diseases. There is now increasing evidence that neurodegener-
ative processes, besides immunologic processes, are important in MS
pathology. Irreversible axonal loss is an important mechanism in the
development of permanent neurological symptoms. Though primary
demyelination may underlie early axonal loss, further progression of
neurodegenerationoccurswhen the compensatory capacity of theCNS is
exceeded and the threshold of axonal loss is reached. Mechanisms
proposed for this loss of nerve ﬁbres includemitochondrial dysfunction,
reduced ATP production and altered expression of sodium channels.
KIF1Bknockoutmicehavebeen reported tohaveCNSabnormalities such
as atrophy [80]. It should be noted however, that any putative functional
role of kinesins in immune cells has been largely left unexplored.
2.7. Rare variants associated with MS susceptibility
Large case–control GWAS primarily expose common variants
contributing to disease pathogenesis with modest effects. Since the
newMS risk loci identiﬁed so far, explain less than1%ofMS risk andHLA
15–40%, other loci remain to be identiﬁed for a more comprehensive
understanding of the genetic susceptibility of MS. Alternative strategies
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Relatively rare variants with at least moderate penetrance most
probably give rise to a higher familial occurrence of MS and so also to
a higher occurrence of MS in a genetic isolate with a founder effect.
Southern Ostrobothnia in Finland is a genetic isolate with an
exceptionally high prevalence and familial occurrence of MS [81–83].
In this isolate the largest pedigree of MS cases could be constructed.
In Finnish MS families enriched with cases from this isolate, linkage of
MS to chromosome5phad beendetected. The IL7R gene is located in the
chromosome 5p region. The 5p locus was studied further in the Finnish
isolate andmonitored for haplotype sharing. This analysis revealed only
modest association at IL7R, whereas most signiﬁcant association was
found with one haplotype covering the C7-FLJ40243 locus. The
identiﬁed risk haplotype (~4% in the general European population) is
relatively rare, but it has obviously become enriched in the southern
Ostrobothnian high-risk MS region (12% of cases). It contains
complement component 7 (C7), again an important factor in the innate
immune system [84]. These results exemplify the power of population
isolates in the identiﬁcation of rare disease alleles.
2.8. Identifying MS risk genes results in a better understanding of MS
pathogenesis?
Still many more markers tested in GWAS have shown association
with MS, although not genome-wide signiﬁcant. Because of the
exceedingly large multiple testing involved in these studies, very few
exceed the genome-wide signiﬁcant threshold and those that donot are
generally neglected. In many cases where loci with small but
measurable genetic effects are involved, it is possible that these loci
represent false negatives. It could be possible that meaningful
combinations of genes, showing only modest evidence of association
inGWAS, can be identiﬁed if they belong to the samebiological pathway
or mechanism.
2.9. Systems biology
In systems biology an integrative approach of available molecular,
physiological, clinical, genetic, gene expression, proteomic and/or
biological information is used with the ultimate goal to identify
pathways involved in the pathogenesis of diseases. Thereby real-
world systems are represented as networks that interconnect different
entities. In this way certain properties can emerge that cannot be
derived from the individual analysis of each of their components [85].
Baranzini and co-workers have recently put current information
on modest genetic effects into a model linked to a human protein
network. They aimed to identify sub-networks containing a higher
proportion of genes associated with MS than expected by chance.
Indeed interesting sub-networks of genes from several immunologic
pathways involved in MS susceptibility were identiﬁed. Part of them
were already known, but also novel neural pathways not identiﬁed
earlier were uncovered [86].
2.10. MS and autoimmune diseases
Intriguing is the fact that most of the above immune related SNPs
have overlapping associations with autoimmune conditions such as
rheumatoid arthritis, inﬂammatory bowel disease, SLE, type I diabetes
and thyroid autoimmunity (see Table 1).
This suggests that in MS and other autoimmune diseases, common
pathways are involved in pathogenesis. If different autoimmune
disorders share susceptibility genes, you would expect relatives to be
not only at greater risk for MS than the general population, but also at
greater risk of other autoimmune disorders. Several studies have
investigated the rate of autoimmune diseases in MS patients and their
biological relatives. The results have been conﬂicting, which may
relate to differences in methodologies and populations studied.It is striking to note that some immunomodulatory treatments in
MS can trigger other AID. The results of a phase II clinical trial with the
lymphocyte-depleting humanized monoclonal antibody alemtuzu-
mab (Campath-1H) show that it is highly effective in the treatment of
early relapsing–remitting MS [87]. A single pulse of treatment results
in rapid, profound and prolonged lymphopenia. Especially CD4+ T-
cells recover slowly, remaining depleted for at least 5 years [88].
However, 30% of patients developed autoimmunity months to years
after pulsed treatment with alemtuzumab. Most people develop
thyroid autoimmunity, mainly Graves' disease, and a few idiopathic
thrombocytopenic purpura (ITP) and in a very few other blood
components are targetted. In addition 5.5% of patients develop
sustained non-thyroid autoantibodies without clinical disease [88].
While the association between lymphopenia and autoimmunity is
well recognized, most lymphopenic subjects do not develop autoim-
munity. It has been shown that autoimmunity arose in those patients
greater T-cell apoptosis and cell cycling in response to treatment. This
phenomenon is driven by higher levels of IL-21. Patients whowent on
to develop autoimmunity had more than 2-fold greater levels of
serum IL-21 than the patients who did not. The production of IL-21
seemed to be genetically determined [87].
The recent indication of a kinesin gene involved in MS, draws for
the ﬁrst time attention to genetic processes in the target organ, the
CNS [43]. Kinesins are responsible for transport of cargo, such as
neurotransmitters and mitochondria, and may be related to several
other neurodegenerative conditions. Tissue damage in MS may be a
result of a disturbed balance between self-protective axonal transport
and immune attacks.
3. Near future
The next step in MS genetics will be to identify the real disease-
mediating variants in the recently discovered genetic risk loci. One of
the major tools will be DNA sequencing around the current SNPs, or
even at the whole genome level.
The identiﬁcation of the exact disease susceptibility genes does not
necessarily deﬁne the pathway involved in disease development, or the
molecular pathway the gene product is involved in. To determine this,
functional studies are necessary [39]. To begin to understand the actions
of the disease-associated variants, their potential effects could ﬁrst be
analysed in cells and tissues from healthy controls that may or may not
have the predisposing genotype. Next, functional and expression
analyses can be done, as the newly discovered genetic variants may
be located in either known or putative regulatory elements, or coding
regions. Themolecular pathways of the genetic variants involved should
of course be analysed in-depth. The simultaneous quantitative analyses
of gene expression will be required as more risk genes become known.
And of course the genetic variation on a genome-wide basis in a large
number of individuals will provide a more thorough understanding of
the molecular networks that are perturbed by the disease-associated
genetic variants [102].
Obtaining immune cells for such functional studies is much more
easy than accessing human CNS cells or tissue. Recent developments in
the ﬁeld of induced pluripotent stem cells (iPS cells) may change this
situation. Those cells can now be generated from ﬁbroblasts [103–105],
keratinocytes [38] and blood progenitor cells [106] and are likely to
revolutionize the generation of in vitro disease models. These models
may allow for functional and expression studies of cells from healthy as
well as MS individuals.
However, variation in gene expression is also affected by factors as
epigenetic modiﬁcation, factors that are not readily identiﬁed by SNP
or DNA sequencing studies. Epigenetic modiﬁcations are markers of
how environmental factors may inﬂuence gene expression and may
be very important in linking genetics to environment. New tools for
the mapping of epigenetic modiﬁcations are becoming possible. The
identiﬁcation of epigenetic processes in demyelination indicates that
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could result in a better understanding of its pathogenesis.
Furthermore the network based approach in system biology can
result in better knowledge of pathogenesis of MS and ﬁnally to better
therapies. The genomic portrait of an individual may allow a predictive
and personalized approach to therapy. In the near future this process
will probably be aided by powerful computers, with information
technologies that will manage the available information from the
patient's tests, thepatient'smedical history and genetic history and ever
evolving scientiﬁc databases.
3.1. Gene–environment interactions
A challenging element of future studies will be the characteriza-
tion of the environmental factors that interact with genetic factors to
ﬁnally cause the disease.
As already described an interaction between vitamin D and HLA-
DRB1*15 has been found even as an interaction between EBV andHLA-
DRB1*15.
Besides EBV and vitamin D numerous bacterial and viral infections
have been described as potential candidates for MS, as they are often
associated with relapses of MS. However no single infection has
consistently been associated with disease [107]. It is unclear how so
many different infections could have a role in the pathogenesis of the
disease and how they might interact with genetic factors, unless their
role is non-speciﬁc, such as in creating inﬂammation or damaging the
blood–brain barrier.
A better understanding of the function of identiﬁed risk genes and
their role in pathogenesis of MS may not only explain how suspected
environmental factors interact with such genetic factors to cause
disease but could also result in the identiﬁcation of additional
environmental risk factors.
3.2. Novel genes in animal models
Work in animal models can also result in a more comprehensive
understanding of the effects of individual genetic variations on
disease development. The experimental autoimmune encephalomy-
elitis (EAE) is a commonly used mouse model for MS. Through this
model relevant molecular pathways in MS have already been
dissected [108]. This has led to the development of new therapies,
most notably natalizumab (Tysabri), an α4 integrin-speciﬁc antibody
that blocks T-cell entry into the CNS [109].
The roles of predisposing genetic variants in the pathogenesis of
MS can be investigated further by the development of a humanized
form of the EAE model in which the animals express transgenes
derived from MS patients. Initially individual disease-associated risk
genes should be introduced, where after mouse lines expressing
individual candidate genes can be cross-bred to allow for pairwise or
higher order comparisons of their contributions to disease pathogen-
esis. Humanized mice have already been used to analyse the varying
effects of different HLA genes in MS and their conclusions are
supported by complementary genetic data from human populations.
However, so far none of the newly identiﬁed non-MHC genetic risk
variants has been analysed in animal models for MS, but this will
become possible in the near future [110].
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